Bruker Corporation Announces AVANCE™-IVDr as a Standardized NMR Platform for Clinical Screening and In Vitro Diagnostics (IVD) Discovery and Validation

Published: Jul 22, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KARLSRUHE, Germany--(BUSINESS WIRE)--Bruker today announces a standardized nuclear magnetic resonance (NMR) spectroscopy platform for its clinical and diagnostics partners that enables cost-effective, high-performance NMR clinical screening and IVD-by-NMR discovery, development and validation of novel NMR assays. The new AVANCE-IVDr system, presently for research use only, is a complete, proven and standardized platform for NMR clinical research and screening, as well as for IVD-by-NMR research. It features high sensitivity and information-rich output at 600 MHz proton-NMR frequency, and incorporates advanced hardware, software, automation, spectral libraries and standard operating procedures (SOPs) for high-performance bio-fluid screening and assay validation. Customer benefits include higher information content and spectral feature differentiation compared to low-field NMR systems, as well as excellent reproducibility, high throughput and potentially dramatically lower cost per sample for better clinical screening and IVD-by-NMR.

Help employers find you! Check out all the jobs and post your resume.

Back to news